CCCC vs HUBB · rev $35.6M vs P/E 28, rev $5.63B
C4 Therapeutics Inc (CCCC) versus Hubbell Inc (HUBB) — a side-by-side from cached financials, not a winner call.
C4 Therapeutics Inc (CCCC) is a biotechnology company listed on US.
Hubbell Inc (HUBB) is a electrical equipment & parts company listed on US.
Latest reported CCCC revenue for 2024-12-31 was $35.6M. Net income was -$105.3M. Revenue was up 71.4% from 2023-12-31 to 2024-12-31. CCCC currently screens at market cap $425.7M.
Latest reported HUBB revenue for 2024-12-31 was $5.63B. Net income was $783.5M. Revenue was up 4.8% from 2023-12-31 to 2024-12-31. HUBB currently screens at market cap $22.14B and trailing P/E 28.0.
CCCC currently screens at market cap $425.7M. HUBB currently screens at market cap $22.14B and trailing P/E 28.0.
Not investment advice. Open the CCCC and HUBB stock pages for the full models.
Not investment advice.